News & Events about Repligen Corp.
Fool.com Headlines
1 year ago
Investors appear to be anticipating an underwhelming first-quarter report from the bioprocessing company.Shares of bioprocessing technology company Repligen (NASDAQ: RGEN) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. That steep decline appears to be connected to the first-quarter ...
Martin Madaus
Repligen Appoints Martin Madaus to Board of Directors
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the ...
Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. ESTWALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, ...
Repligen (NASDAQ:RGEN Get Rating) had its price objective lowered by investment analysts at SVB Leerink from $230.00 to $200.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an outperform rating on the biotechnology companys stock. SVB ...
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41stAnnual J.P. Morgan Healthcare conference being held January 9-12 in San Francisco. Tony J. ...